ABBOTT'S XIENCE V DRUG ELUTING STENT WINS INNOVATION AWARD.Abbott has received a 2008 Chicago Innovation Award for its XIENCE V(TM) Everolimus Eluting Coronary Stent coronary stent Intracoronary stent Cardiology An expandable tubular device which can be inserted percutaneously, and left within a coronary artery lumen to maintain its patency Pros Clinical and angiographic outcomes are better with intracoronary artery stent System. Based on the product's innovative design and strong clinical data, the next-generation drug eluting stent represents a significant advance in the treatment of coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. . Abbott's XIENCE V stent was approved by the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) and launched in July 2008, providing a new treatment option for the nearly 13 million Americans with coronary artery disease, the leading cause of death for both men and women in the United States. Stents are designed to prop open an artery that has become clogged by plaque build-up and restore blood flow to the heart. A drug eluting stent releases a medication (everolimus, in the case of XIENCE V) in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is the only drug eluting stent to demonstrate superiority over the previous market-leading drug eluting stent in two randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , pivotal clinical trials -- and XIENCE V has become the market-leading drug eluting stent in just three months since launch. This is the fourth Chicago Innovation Award that Abbott has received in six years. Most recently, the company's m2000(TM) molecular diagnostic instrument in combination with the RealTime HIV-1 viral load test Viral load test A new blood test for monitoring the speed of HIV replication in AIDS patients. The viral load test is based on PCR techniques and supplements the CD4+ cell count tests. received the honor in 2007. In 2005, the company's PathVysion(TM) breast cancer test received the honor, and in 2003, HUMIRA(TM), the first human monoclonal antibody drug for rheumatoid arthritis, won the award. "At Abbott, we are proud to be in the business of developing innovative treatments that improve and save lives," said Miles D. White Miles D. White is an American businessman. He is currently chairman of the board and chief executive officer of Abbott. He is also chairman of the Federal Reserve Bank of Chicago. , chairman and chief executive officer, Abbott. "Receiving the Chicago Innovation Award is a great testament to our constant pursuit of innovation, which is driven by finding meaningful solutions -- like XIENCE V -- for the patients who rely on us." Sponsored by Kuczmarski and Associates and BusinessWeek, the Chicago Innovation Awards The Chicago Innovation Awards was created by the Chicago Sun-Times and Kuczmarski & Associates in 2002. Each year the Awards recorgnize 10 Chicago area businesses, nonprofits, and government organizations that develop the year’s most innovative new products and services. create awareness of the contributions of Chicago-area companies and organizations in developing innovative products and services that uniquely fill unmet needs and change lives. About XIENCE V XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform has the thinnest stent structure available and is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery. Long-term results with XIENCE V in the SPIRIT III pivotal U.S. clinical trial demonstrated a 45 percent reduction in the risk of major adverse cardiac events (MACE) compared to the TAXUS(R) paclitaxel-eluting coronary stent system at two years. XIENCE V demonstrated a 32 percent reduction in target vessel failure (TVF TVF Target Vessel Failure (cardiology) TVF Time Variant Filter TVF Thief River Falls, MN, USA - Thief River Falls Municipal (Airport Code) TVF Tactile Vocal Fremitus TVF Turkiye Voleybol Federasyonu , cardiac events related to the stented vessel) compared to TAXUS at two years. XIENCE V also demonstrated a low rate of stent thrombosis between one and two years, defined as very late stent thrombosis late stent thrombosis Cardiology The scar-induced closure of a previously stenosed coronary artery, a complication in ±20% of Pts who have undergone stenting for CAD. See Stent. Cf In-stent restenosis. , per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.3 percent for XIENCE V and 1.0 percent for TAXUS). XIENCE V met its primary endpoint in the SPIRIT III clinical trial with a statistically significant 50 percent reduction in in-segment late loss (vessel renarrowing) at eight months compared to TAXUS. The XIENCE V stent is available on both over-the-wire (OTW OTW Otherwise OTW Off The Wall OTW On the Way OTW On the Whole OTW Of The World (online TV network) OTW On The Web OTW Out the Window (display/graphics) OTW On The Water ) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery-system because it provides physicians additional flexibility to work as single operators during stent procedures. XIENCE V was launched in Europe and other international markets in October 2006 and is an investigational device in Japan where it is currently under review by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties. Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com/. About Abbott Abbott (NYSE NYSE See: New York Stock Exchange :ABT ABT About ABT Abteilung (German: Department) ABT Abbott Laboratories (stock symbol) ABT American Ballet Theatre ABT Associação Brasileira de Telemarketing ABT Abort ABT Availability Based Tariff ) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries. For more information, http://www.abbott.com or call 408/624-0314. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion